Skip to main navigation Skip to search Skip to main content

A Systematic Review of Pharmacovigilance Systems in Developing Countries Using the WHO Pharmacovigilance Indicators

Research output: Contribution to journalArticlepeer-review

342 Downloads (Pure)

Abstract

Background
In the context of the growth of pharmacovigilance (PV) among developing countries, this systematic review aims to synthesise current research evaluating developing countries’ PV systems’ performance.
Methods
EMBASE, MEDLINE, CINAHL Plus and Web of Science were searched for peer-reviewed studies published in English between 2012 and 2021. Reference lists of included studies were screened. Included studies were quality assessed using Hawker et al.'s nine-item checklist; data were extracted using the WHO PV indicators checklist. Scores were assigned to each group of indicators and used to compare countries’ PV performance.
Results
Twenty-one unique studies from 51 countries were included. Of a total possible quality score of 36, most studies were rated medium (n = 7 studies) or high (n = 14 studies). Studies obtained an average score of 17.2 out of a possible 63 of the WHO PV indicators. PV system performance in all 51 countries was low (14.86/63; range: 0–26). Higher average scores were obtained in the ‘Core’ (9.27/27) compared to ‘Complementary’ (5.59/36) indicators. Overall performance for ‘Process’ and ‘Outcome’ indicators was lower than that of ‘Structural’.
Conclusion
This first systematic review of studies evaluating PV performance in developing countries provides an in-depth understanding of factors affecting PV system performance.
Original languageEnglish
Pages (from-to)717-743
Number of pages27
JournalTherapeutic Innovation & Regulatory Science
Volume56
Issue number5
DOIs
Publication statusPublished - 3 Jun 2022

Keywords

  • Pharmacovigilance
  • Adverse Drug Reaction Reporting Systems
  • Developing countries
  • Evaluation

Fingerprint

Dive into the research topics of 'A Systematic Review of Pharmacovigilance Systems in Developing Countries Using the WHO Pharmacovigilance Indicators'. Together they form a unique fingerprint.

Cite this